Comment on 'Impact of performance status on non-small cell lung cancer patients with a PD-L1 tumour proportion score ?50% treated with front-line pembrolizumab'
| dc.contributor.author | Kocak, Mehmet Zahid | |
| dc.date.accessioned | 2024-02-23T14:17:18Z | |
| dc.date.available | 2024-02-23T14:17:18Z | |
| dc.date.issued | 2021 | |
| dc.department | NEÜ | en_US |
| dc.description.abstract | [Abstract Not Availabe] | en_US |
| dc.identifier.doi | 10.1080/0284186X.2021.1889028 | |
| dc.identifier.endpage | 565 | en_US |
| dc.identifier.issn | 0284-186X | |
| dc.identifier.issn | 1651-226X | |
| dc.identifier.issue | 4 | en_US |
| dc.identifier.pmid | 33612057 | en_US |
| dc.identifier.scopus | 2-s2.0-85101234364 | en_US |
| dc.identifier.scopusquality | Q1 | en_US |
| dc.identifier.startpage | 564 | en_US |
| dc.identifier.uri | https://doi.org/10.1080/0284186X.2021.1889028 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12452/13042 | |
| dc.identifier.volume | 60 | en_US |
| dc.identifier.wos | WOS:000620048200001 | en_US |
| dc.identifier.wosquality | Q2 | en_US |
| dc.indekslendigikaynak | Web of Science | en_US |
| dc.indekslendigikaynak | Scopus | en_US |
| dc.indekslendigikaynak | PubMed | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | Taylor & Francis Ltd | en_US |
| dc.relation.ispartof | Acta Oncologica | en_US |
| dc.relation.publicationcategory | Diğer | en_US |
| dc.rights | info:eu-repo/semantics/openAccess | en_US |
| dc.subject | [Keyword Not Available] | en_US |
| dc.title | Comment on 'Impact of performance status on non-small cell lung cancer patients with a PD-L1 tumour proportion score ?50% treated with front-line pembrolizumab' | en_US |
| dc.type | Editorial Material | en_US |
